

Inhibitor Working Party

Membership

P Collins	Chairman
D Hart	Secretary
E Chalmers	
C Hay	
R Liesner	
B Palmer	
S Rangarajan	
K Talks	
M Williams	

The working party reformed in March 2011

There have been two face to face meetings this year and eight teleconferences.

Activities

National immune tolerance induction protocol

A protocol for first line ITI for minimally treated severe patients has been developed by the working party in collaboration with the paediatric working party and this has been ratified by the advisory committee. This protocol is based on the recently published inhibitor guidelines.

The protocol has been adopted by the English Clinical Reference Group and all first line ITI for children with severe haemophilia A are expected to be treated according to this protocol and outcomes reported to the NHD.

Analysis of data held by NHD

Inhibitor surveillance in previously treated patients

A paper describing the outcomes of switching product following the previous tender has been submitted to Haemophilia and is undergoing peer review. The results do not suggest any increase in inhibitor formation related to switching although, even with the large number of patients available for UKHCDO to analyse, the study is underpowered.

Inhibitor rates associated with brands of recombinant factor VIII

A recent study has suggested that the risk of a PUP developing an inhibitor varies with the brand of recombinant factor VIII (NEJM 368:231-9, 2013). It is important that this finding is investigated in other cohorts of patients. The NHD has identified all PUPs first treated in the UK between 2000 and 2011 and is investigating the rate of inhibitor development associated with each product. This exercise has been extended so that a multivariate analysis can be

performed to include the main known risk factors for inhibitor development (mutation, family history, ethnicity and intensive treatment).

Centres have been asked to clarify important data points and to ensure that the cohort investigated is appropriate and the response to data requests has been very positive. This work has been the main focus of the working party and a major exercise of data collection and cleaning has been performed in collaboration with the NHD. The data analysis has been performed in consultation with the executive committee and the advisory committee.

The results will be an important contribution to patient safety and will be reported soon.

Acquired haemophilia survey

A survey of UK treaters regarding immunosuppressive treatment of acquired haemophilia A has been completed and accepted for publication as a letter in Haemophilia. The study was led by Dr Batty from the Royal London Hospital.

Future of the working party

The inhibitor working completed its three year term in March 2014 and has been reconstituted under the chair of Dr Hart. The composition of the new working party was not known at the time of writing.

Dr Peter Collins
Chairman, Inhibitor Working Party
September 2014